Scientists have developed an agent that reverses the anticoagulation effects of dabigatran, a blood-thinning drug developed by Boehringer Ingelheim. The antidote is a fragment of a monoclonal antibody that helps eliminate the drug from the bloodstream. Complete reversal of the drug's anticoagulation effect was seen among healthy volunteers who received the antidote through five-minute intravenous infusions after four days of taking dabigatran.

Full Story:

Related Summaries